A phase I trial to investigate JHL1922 to improve pulmonary function in cystic fibrosis patients

Trial Profile

A phase I trial to investigate JHL1922 to improve pulmonary function in cystic fibrosis patients

Planning
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs JHL-1922 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2017 New trial record
    • 20 Dec 2017 According to a JHL Biotech media release, the company has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority. The clinical trial will be conducted in the Netherlands beginning March 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top